Anti-CD43 antibody and use thereof for cancer treatment
Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.
1. An anti-CD43 antibody or an antigen-binding fragment thereof, comprising
a CDR1H of SEQ ID NO: 111,
a CDR2H of SEQ ID NO: 114,
a CDR3H of SEQ ID NO: 118,
a CDR1L of SEQ ID NO: 119,
a CDR2L of SEQ ID NO: 122, 123, or 124, and
a CDR3L of SEQ ID NO: 125.
2. The anti-CD43 antibody or an antigen-binding fragment thereof of claim 1 , comprising:
a CDR1 H of SEQ ID NO: 111,
a CDR2H of SEQ ID NO: 114,
a CDR3H of SEQ ID NO: 118,
a CDR1L of SEQ ID NO: 119,
a CDR2L of SEQ ID NO: 124, and
a CDR3L of SEQ ID NO: 125.
3. The anti-CD43 antibody or an antigen-binding fragment thereof of claim 1 , comprising:
a heavy chain variable region of SEQ ID NO: 6; and
a light chain variable region of SEQ ID NO: 107, 108, or 109.
4. A conjugate comprising:
the anti-CD43 antibody or an antigen-binding fragment thereof of claim 1 ; and
at least one selected from the group consisting of a cytotoxic material and a labeling material.
5. The conjugate of claim 4 , wherein the cytotoxic material is at least one selected from the group consisting of ricin, saporin, gelonin, momordin, debouganin, diphtheria toxin, pseudomonas toxin, radioisotopes, duocarmycin, monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)maytansine (DM1), and pyrrolobenzodiazepine (PBD) dimer.
6. A pharmaceutical composition comprising:
the anti-CD43 antibody or an antigen-binding fragment thereof of claim 1 , and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising:
the conjugate of claim 5 , and
a pharmaceutically acceptable carrier.